Phase II study of cisplatin, etoposide and paclitaxel in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction.
dc.contributor.author | Sharma, Atul | en_US |
dc.contributor.author | Raina, V | en_US |
dc.contributor.author | Lokeshwar, N | en_US |
dc.contributor.author | Deo, S V S | en_US |
dc.contributor.author | Shukla, N K | en_US |
dc.contributor.author | Mohanti, B K | en_US |
dc.date.accessioned | 2009-05-28T06:30:45Z | |
dc.date.available | 2009-05-28T06:30:45Z | |
dc.date.issued | 2006-01-10 | en_US |
dc.description.abstract | BACKGROUND: Unresectable and metastatic gastric cancers carry a poor and dismal prognosis. Several phase II studies have identified effective anticancer drugs. AIMS: To evaluate safety and efficacy of low-dose cisplatin, etoposide and paclitaxel (CEP) based combination chemotherapy in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction. SETTING AND DESIGN: Prospective single-arm phase II study. MATERIALS AND METHODS: Thirty-three patients were enrolled onto this study, out of which, all but one received cisplatin 15 mg/m 2, etoposide 40 mg/m 2 and paclitaxel 50 mg/m 2, given on day 1 and 4 every week for three weeks in a 28-day cycle. Survival analysis was done using SPSS program. RESULTS: Median age of group was 56 years. Twenty-five were males. Twenty-nine had metastatic/inoperable disease and four patients had recurrent disease. Liver was the commonest metastatic site seen in 15 patients. With a median of 2 cycles per patient, a total of 76 cycles was administered. Grade III or IV toxicity were seen in 11 (35%) patients; diarrhea, 5 patients; vomiting, 3 patients; and neutropenia, 7 patients, 5 of whom also had fever). One patient died of neutropenic fever. Best responses, seen in 32 evaluable patients, were 2 CR (6.1%), 21 PR (63%) and 3 SD (9.2%). Four patients were considered operable after chemotherapy. With median follow-up of 11 months in surviving patients, median OS was 10 months and PFS was 8 months. Median OS was 13 months in responders versus 8 months in nonresponders (P =0.04). Seven patients survived> 12 months. CONCLUSION: Combination of low-dose CEP shows good clinical response and an acceptable toxicity profile in advanced or metastatic adenocarcinoma of gastric/gastroesophageal cancers. Whether addition of 5 FU or capecitabine adds to the benefit should be explored. This may be tested with other standard/conventional protocols in a randomized fashion. | en_US |
dc.description.affiliation | Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India. atul1@hotmail.com | en_US |
dc.identifier.citation | Sharma A, Raina V, Lokeshwar N, Deo SV, Shukla NK, Mohanti BK. Phase II study of cisplatin, etoposide and paclitaxel in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction. Indian Journal of Cancer. 2006 Jan-Mar; 43(1): 16-9 | en_US |
dc.identifier.uri | https://imsear.searo.who.int/handle/123456789/49953 | |
dc.language.iso | eng | en_US |
dc.source.uri | https://www.indianjcancer.com | en_US |
dc.subject.mesh | Adenocarcinoma --drug therapy | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols --adverse effects | en_US |
dc.subject.mesh | Cisplatin --administration & dosage | en_US |
dc.subject.mesh | Esophagogastric Junction --drug effects | en_US |
dc.subject.mesh | Etoposide --administration & dosage | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.subject.mesh | Neoplasm Recurrence, Local --drug therapy | en_US |
dc.subject.mesh | Paclitaxel --administration & dosage | en_US |
dc.subject.mesh | Prospective Studies | en_US |
dc.subject.mesh | Stomach Neoplasms --drug therapy | en_US |
dc.subject.mesh | Survival Rate | en_US |
dc.title | Phase II study of cisplatin, etoposide and paclitaxel in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction. | en_US |
dc.type | Clinical Trial, Phase II | en_US |
dc.type | Journal Article | en_US |
Files
License bundle
1 - 1 of 1